NB
Noam Band
CEO & Director
Chief Executive
born 1970
LOADING SNAPSHOT
Fetching the books…
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.
For commercial pharma: watch patent cliffs and competition. For pre-revenue biotech: cash runway and trial readouts.
Mixed signals — interesting but with caveats. Worth a deeper look before committing capital.
| Period | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2021-12-31 | — | — | — | — | — |
| 2022-12-31 | — | — | ₪-880.00K | ₪-1.35M | — |
| 2023-12-31 | — | — | ₪-765.00K | ₪-1.78M | — |
| 2024-12-31 | — | — | ₪-775.00K | ₪-1.03M | — |
| 2025-12-31 | — | — | ₪-1.38M | ₪-6.97M | — |
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.